Back
Tim Garnett MD
Tim Garnett M.D, is a distinguished veteran of the pharmaceutical industry. Most recently, Dr Garnett spent over 20 years at Eli Lilly in roles of increasing responsibility including serving as Chief Medical Officer from 2008 until 2021. At Lilly he led successful development of therapeutics in women’s health care, endocrinology and neuroscience through regulatory approval and successful launch in multiple geographies including the US, Europe, China and Japan. Dr Garnett has extensive experience leading clinical development, portfolio management, medical, regulatory and safety functions as well as a strategic understanding of the landscape for metabolic therapeutics.
In addition to his role as equity partner at Recode, Tim is also a Board Chair of Ophirex, Board Member of Carmot Theraputics and a member of the Advisory Panel of Cambridge Innovation Capital. He holds a Bachelor of Medicine, Bachelor of Surgery (MBBS), is a Fellow of the Faculty of Pharmaceutical Medicine (FFPM), and a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).
